188 related articles for article (PubMed ID: 36855173)
1. Development of a screening platform to discover natural products active against SARS-CoV-2 infection using lung organoid models.
Lee JE; Jeong SY; Li Z; Kim HY; Kim HW; Yoo MJ; Jang HJ; Kim DK; Cho N; Yoo HM; Kim KH
Biomater Res; 2023 Mar; 27(1):18. PubMed ID: 36855173
[TBL] [Abstract][Full Text] [Related]
2. The use of Pseudotyped Coronaviruses for the Screening of Entry Inhibitors: Green Tea Extract Inhibits the Entry of SARS-CoV-1, MERSCoV, and SARS-CoV-2 by Blocking Receptor-spike Interaction.
Joseph J; Karthika T; Das VRA; Raj VS
Curr Pharm Biotechnol; 2022; 23(8):1118-1129. PubMed ID: 34375189
[TBL] [Abstract][Full Text] [Related]
3. Screening of Natural Products Inhibitors of SARS-CoV-2 Entry.
González-Maldonado P; Alvarenga N; Burgos-Edwards A; Flores-Giubi ME; Barúa JE; Romero-Rodríguez MC; Soto-Rifo R; Valiente-Echeverría F; Langjahr P; Cantero-González G; Sotelo PH
Molecules; 2022 Mar; 27(5):. PubMed ID: 35268843
[TBL] [Abstract][Full Text] [Related]
4. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
[TBL] [Abstract][Full Text] [Related]
5. Potential natural products that target the SARS-CoV-2 spike protein identified by structure-based virtual screening, isothermal titration calorimetry and lentivirus particles pseudotyped (Vpp) infection assay.
Chen GY; Pan YC; Wu TY; Yao TY; Wang WJ; Shen WJ; Ahmed A; Chan ST; Tang CH; Huang WC; Hung MC; Yang JC; Wu YC
J Tradit Complement Med; 2022 Jan; 12(1):73-89. PubMed ID: 34549024
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of green tea catechin, (-)-epigallocatechin-3-
Dinda B; Dinda S; Dinda M
Phytomed Plus; 2023 Feb; 3(1):100402. PubMed ID: 36597465
[TBL] [Abstract][Full Text] [Related]
7. Screening S protein - ACE2 blockers from natural products: Strategies and advances in the discovery of potential inhibitors of COVID-19.
Ma LL; Liu HM; Liu XM; Yuan XY; Xu C; Wang F; Lin JZ; Xu RC; Zhang DK
Eur J Med Chem; 2021 Dec; 226():113857. PubMed ID: 34628234
[TBL] [Abstract][Full Text] [Related]
8. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
9. Computational profiling of natural compounds as promising inhibitors against the spike proteins of SARS-CoV-2 wild-type and the variants of concern, viral cell-entry process, and cytokine storm in COVID-19.
Kar P; Saleh-E-In MM; Jaishee N; Anandraj A; Kormuth E; Vellingiri B; Angione C; Rahman PKSM; Pillay S; Sen A; Naidoo D; Roy A; Choi YE
J Cell Biochem; 2022 May; 123(5):964-986. PubMed ID: 35342986
[TBL] [Abstract][Full Text] [Related]
10. GMI, a protein from Ganoderma microsporum, induces ACE2 degradation to alleviate infection of SARS-CoV-2 Spike-pseudotyped virus.
Yeh H; Vo DNK; Lin ZH; Ho HPT; Hua WJ; Qiu WL; Tsai MH; Lin TY
Phytomedicine; 2022 Aug; 103():154215. PubMed ID: 35691077
[TBL] [Abstract][Full Text] [Related]
11. Human Organotypic Airway and Lung Organoid Cells of Bronchiolar and Alveolar Differentiation Are Permissive to Infection by Influenza and SARS-CoV-2 Respiratory Virus.
Ekanger CT; Zhou F; Bohan D; Lotsberg ML; Ramnefjell M; Hoareau L; Røsland GV; Lu N; Aanerud M; Gärtner F; Salminen PR; Bentsen M; Halvorsen T; Ræder H; Akslen LA; Langeland N; Cox R; Maury W; Stuhr LEB; Lorens JB; Engelsen AST
Front Cell Infect Microbiol; 2022; 12():841447. PubMed ID: 35360113
[TBL] [Abstract][Full Text] [Related]
12. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
13. Generation of Angiotensin-Converting Enzyme 2/Transmembrane Protease Serine 2-Double-Positive Human Induced Pluripotent Stem Cell-Derived Spheroids for Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Drug Evaluation.
Higashi-Kuwata N; Yabe SG; Fukuda S; Nishida J; Tamura-Nakano M; Hattori SI; Okochi H; Mitsuya H
Microbiol Spectr; 2022 Dec; 10(6):e0349022. PubMed ID: 36314907
[TBL] [Abstract][Full Text] [Related]
14. Potential antiviral activity of isorhamnetin against SARS-CoV-2 spike pseudotyped virus in vitro.
Zhan Y; Ta W; Tang W; Hua R; Wang J; Wang C; Lu W
Drug Dev Res; 2021 Dec; 82(8):1124-1130. PubMed ID: 33847382
[TBL] [Abstract][Full Text] [Related]
15. Stapled Peptides Based on Human Angiotensin-Converting Enzyme 2 (ACE2) Potently Inhibit SARS-CoV-2 Infection
Curreli F; Victor SMB; Ahmed S; Drelich A; Tong X; Tseng CK; Hillyer CD; Debnath AK
mBio; 2020 Dec; 11(6):. PubMed ID: 33310780
[TBL] [Abstract][Full Text] [Related]
16. Identification of Candidate COVID-19 Therapeutics using hPSC-derived Lung Organoids.
Han Y; Yang L; Duan X; Duan F; Nilsson-Payant BE; Yaron TM; Wang P; Tang X; Zhang T; Zhao Z; Bram Y; Redmond D; Houghton S; Nguyen D; Xu D; Wang X; Uhl S; Huang Y; Johnson JL; Xiang J; Wang H; Pan FC; Cantley LC; tenOever BR; Ho DD; Evans T; Schwartz RE; Chen HJ; Chen S
bioRxiv; 2020 May; ():. PubMed ID: 32511403
[TBL] [Abstract][Full Text] [Related]
17. The Human Nose Organoid Respiratory Virus Model: an
Rajan A; Weaver AM; Aloisio GM; Jelinski J; Johnson HL; Venable SF; McBride T; Aideyan L; Piedra FA; Ye X; Melicoff-Portillo E; Yerramilli MRK; Zeng XL; Mancini MA; Stossi F; Maresso AW; Kotkar SA; Estes MK; Blutt S; Avadhanula V; Piedra PA
mBio; 2021 Feb; 13(1):e0351121. PubMed ID: 35164569
[TBL] [Abstract][Full Text] [Related]
18. In Silico Screening of Bioactive Compounds of Representative Seaweeds to Inhibit SARS-CoV-2 ACE2-Bound Omicron B.1.1.529 Spike Protein Trimer.
Bharathi M; Sivamaruthi BS; Kesika P; Thangaleela S; Chaiyasut C
Mar Drugs; 2022 Feb; 20(2):. PubMed ID: 35200677
[TBL] [Abstract][Full Text] [Related]
19. An anti-inflammatory and anti-fibrotic proprietary Chinese medicine nasal spray designated as Allergic Rhinitis Nose Drops (ARND) with potential to prevent SARS-CoV-2 coronavirus infection by targeting RBD (Delta)- angiotensin converting enzyme 2 (ACE2) binding.
Yip KM; Lee KM; Ng TB; Xu S; Yung KKL; Qu S; Cheung AKL; Sze SCW
Chin Med; 2022 Jul; 17(1):88. PubMed ID: 35897044
[TBL] [Abstract][Full Text] [Related]
20. Two Different Therapeutic Approaches for SARS-CoV-2 in hiPSCs-Derived Lung Organoids.
Spitalieri P; Centofanti F; Murdocca M; Scioli MG; Latini A; Di Cesare S; Citro G; Rossi A; Orlandi A; Miersch S; Sidhu SS; Pandolfi PP; Botta A; Sangiuolo F; Novelli G
Cells; 2022 Apr; 11(7):. PubMed ID: 35406799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
